Indicaton

Epilepsy

Milestone: H2 2023

ADX71149 for the treatment of epilepsy.

ADX71149 is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM).

Therapeutic indications
Type of product
Table
  • Phase
    Phase II started
  • Partnering status
    Partnered
  • Partner
    Janssen Pharmaceutica